Inhibition of Bradykinin in COVID-19 Infection With Icatibant

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

June 9, 2023

Study Completion Date

July 7, 2023

Conditions
SARS CoV 2 Infection
Interventions
DRUG

Icatibant

"Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."

DRUG

0.9% Sodium Chloride Injection

"Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."

Trial Locations (1)

BT14 6AB

Mater Infirmorum Hospital, Belfast

All Listed Sponsors
collaborator

Queen's University, Belfast

OTHER

lead

Belfast Health and Social Care Trust

OTHER